Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
47.23
+1.53 (3.35%)
Oct 3, 2025, 3:20 PM EDT - Market open
Revolution Medicines Stock Forecast
Stock Price Forecast
The 15 analysts that cover Revolution Medicines stock have a consensus rating of "Strong Buy" and an average price target of $74.47, which forecasts a 57.68% increase in the stock price over the next year. The lowest target is $64 and the highest is $99.
Price Target: $74.47 (+57.68%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 7 | 9 | 9 |
| Buy | 5 | 5 | 5 | 6 | 7 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 13 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $65 → $73 | Strong Buy | Maintains | $65 → $73 | +54.56% | Sep 12, 2025 |
| Raymond James | Raymond James | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | +52.45% | Sep 12, 2025 |
| Wedbush | Wedbush | Buy Maintains $73 → $77 | Buy | Maintains | $73 → $77 | +63.03% | Sep 11, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $67 → $70 | Buy | Maintains | $67 → $70 | +48.21% | Sep 11, 2025 |
| Needham | Needham | Strong Buy Maintains $56 → $66 | Strong Buy | Maintains | $56 → $66 | +39.74% | Sep 11, 2025 |
Financial Forecast
Revenue This Year
5.17M
Revenue Next Year
28.65M
from 5.17M
Increased by 454.11%
EPS This Year
-5.41
from -3.58
EPS Next Year
-6.02
from -5.41
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 43.8M | 149.6M | |||
| Avg | 5.2M | 28.7M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 2,793.6% | |||
| Avg | - | 454.1% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.92 | -4.69 | |||
| Avg | -5.41 | -6.02 | |||
| Low | -5.51 | -7.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.